Freshly collected chronic lymphocytic leukemia B cells (B-CLL
fected cells induces them to become efficient APC for the generation of allogeneic proliferative and cytotoxic T cell responses, and whether these alloantigen-primed T cells are Introduction capable of exerting cytotoxic activity against unstimulated B-CLL cells. Our findings indicate that CD40 should be Chronic lymphocytic leukemia of B cell origin (B-CLL) is the considered as a potential target for immunotherapy. most common leukemia in the western hemisphere, accounting for almost one third of all cases. 1 The disease is incurable with conventional treatment programs, and patients with Materials and methods advanced B-CLL have a mean survival of less than 5 years. 2 New approaches, including treatment with cytokines such as Patients interferon-␣ (IFN-␣), have not been very effective. 3, 4 The recent demonstration of major histocompatibility comPeripheral blood samples were collected from five healthy plex (MHC)-restricted recognition of autologous B-CLL cells donors and from five newly diagnosed patients with B-CLL. by tumor-specific T cells 5, 6 indicates that B-CLL cells poten-B-CLL was diagnosed on the basis of clinical, morphological, tially present tumor-specific peptides (mutant proteins, and immunophenotypic features. idiotypic determinants of the tumor immunoglobulin) in the context of MHC molecules. However, only sparse evidence exists that tumor cells in general can induce a clinically sigMonoclonal antibodies and other reagents nificant antitumor T cell response in the autologous host. 7 Moreover, B-CLL cells are inefficient stimulators even for allo-
The mouse monoclonal antibodies (mAb) used for flow cytogeneic T cells. 8, 9 Besides the interaction between peptide metry were anti-CD3, anti-CD4, anti-CD8, anti-CD11a (LFAantigen/MHC on antigen-presenting cells (APC) and the anti-1), anti-CD19, anti-CD25, anti-CD54 (ICAM-1), anti-CD80 gen-specific T cell receptor, T cells are known to require at (anti-B7-1), anti-kappa, anti-lambda, anti-HLA-DR (MHC class least one accessory signal for activation. 10 This second signal II), and the appropriate mouse immunoglobulin (Ig) isotype is delivered by costimulatory molecules on the APC through controls, from Becton Dickinson (Erembodegem, Belgium). their counter-receptors on the T cells. 10 Particular interest has Anti-CD50 (ICAM-3) was from Biosource International recently been shown in the members of the B7 family, which (Camarillo, CA, USA). Anti-CD58 (LFA-3) was from Immunoappear to be the most important costimulatory molecules on tech (Marseille, France). The anti-B7-2 mAb FUN-1 (anti-CD86) was from Pharmingen (San Diego, CA, USA). Anti-MHC class I was from One Lambda (Canoga Park, CA, USA).
Correspondence: J Ceuppens, Laboratory of Experimental Immu-
The hybridoma producing mAb OKT3 (anti-CD3) used for containing the cDNA for human CD40L, 25 by lipofection (DOTAP; Boehringer Mannheim). The transfected cells were selected in the presence of 200 g/ml G418-sulphate (Gibco).
Immunofluorescence studies
The day before transfection, cells were seeded in a 10 cm dish at 8 × 10 5 cells per dish. Transfection was performed with Three-and two-color analyses were performed by direct immunofluorescence with FITC (fluorescein isothiocyanate)-, 7.5 g plasmid. Medium was replaced after 16 h. Selection medium was added after 24 h. Neo-resistant clones were PE (phycoerythrin)-, and PerCP (peridinin chlorophyll protein)-conjugated mAb. Briefly, 100 l cell suspension selected and screened for CD40L expression by staining with affinity-purified CD40-IgM (3 g/ml; the CD40-IgM-produc-(cultured lymphocytes or peripheral blood, eventually diluted with phosphate-buffered saline to a maximum of 10 × 10 6 ing hybridoma was kindly provided by Dr P Lane, Basel Institute for Immunology, Basel, Switzerland), followed by a cells/ml) was incubated with the directly conjugated mAb. After 15 min, the cells were either washed (cultured biotinylated anti-hIgM mAb (1D12, IgG1) or an irrelevant mouse IgG1 mAb (3G5, IgG1) and streptavidin-PE (Becton lymphocytes), or incubated with FACS lysing solution (Becton Dickinson) for 10 minutes to lyse the erythrocytes (peripheral Dickinson). The cells were then analysed on a FACStar instrument (Becton Dickinson). blood). The cells were then centrifuged and fixed in 0.5 ml of a 0.5% paraformaldehyde/PBS solution. Two-and three-color immunofluorescence analyses were performed on a FACScan flow cytometer (Becton Dickinson). Data obtained by flow Activation of B-CLL cells by coculture with 3T6/CD40L mouse fibroblasts cytometry were analyzed by gating the lymphocytes using forward and side light scatter in the Lysis II software program (Becton Dickinson). Ten thousand cells were routinely PBMC containing 1 × 10 6 B-CLL cells were cultured for 22 h in complete medium, with 0.375 × 10 6 mitomycin C analyzed for each marker combination.
(50 g/ml)-treated 3T6/CD32 mouse fibroblasts, or 0.375 × 10 6 mitomycin C-treated 3T6/CD40L mouse fibroblasts in 24-well flat-bottom Falcon tissue culture plates Cell separation (Becton Dickinson) in 1 ml of medium. All cultures were performed at 37°C in a 5% CO 2 atmosphere. After coculture, the Peripheral blood mononuclear cells (PBMC) were isolated by centrifuging the blood over a Lymphoprep (density 1.077) cells were collected and purified by magnetic immunoselection using anti-CD19-coated Dynabeads (Dynal) and gradient (Nycomed, Oslo, Norway). The cells were resuspended in RPMI 1640 culture medium (Gibco), supplemented Detachabead (Dynal) for immunophenotyping and coculture with allogeneic T cells. with 2 mM L-glutamine (Gibco); 100 U/ml penicillin (Gibco); 100 g/ml streptomycin (Gibco); and 10% iron-supplemented bovine calf serum (BCS; Hyclone, Logan, UT, USA). For purification of CD3 + lymphocytes, monocytes were first removed Stimulation of allogeneic T cells with B-CLL cells by cold agglutination, by rotating the tubes for 30 min at 4°C. The agglutinated monocytes were sedimented out and the For primary stimulation, purified CD4 + , CD8 + , or CD3 + T cells were cultured with irradiated (40 Gy) B-CLL cells at a 1/4 lymphocytes were further purified using complement-fixing anti-NK, anti-monocyte mAb and Lympho-KWIK-T (One stimulator/responder ratio for 5-7 days. For inhibition experiments, anti-CD80 or anti-CD86 mAb (both at 2 g/ml, final Lambda, Los Angeles, CA, USA). For purification of CD4 + ,
CD8
+ and CD19 + lymphocytes, magnetic immunoselection on concentration), or CTLA4-Ig fusion protein (10 g/ml, final concentration) were added from the beginning of the culture PBMC with anti-CD4-, anti-CD8-, and anti-CD19-coated Dynabeads (Dynal, Oslo, Norway) respectively, was used.
period. After 5-7 days, the cells were harvested and resuspended in medium for immunophenotyping and analysis of The beads were applied with a bead-to-target ratio of 3:1 for CD4 + and CD8 + lymphocytes, and a bead-to-target ratio of cytotoxic capacity, or for restimulation. In the latter case, the cells were first rested in medium during 1 day in the absence 5:1 for CD19 + lymphocytes. The selected cells were detached from the beads using Detachabead solution (Dynal). Greater of the stimulator cells. The T cells were then restimulated with irradiated tumor cells at a 1/4 stimulator/responder ratio. than 95% purification was achieved for CD4 + and CD8 + cells, and greater than 99% purification was achieved for CD3
+ and Three to four days later, the cells were harvested and resuspended in medium for immunophenotyping and analysis of CD19 England) for 1-2 h in the case of P815 target cells and over- in a CO 2 incubator. Afterwards, 100 l of the supernatant of each well was collected and counted in a gamma counter.
Results are expressed either as percentage 51 Cr release of P815 CD50, CD54 and CD58 adhesion molecules, and of CD80 cells (for evaluation of the LAK activity), or as percentage 51 Cr and CD86 costimulatory molecules on peripheral blood Brelease of unstimulated B-CLL cells (for evaluation of the CLL cells. As shown in Table 2 , peripheral blood B-CLL cells tumor-directed cytotoxicity). The following formula was used nearly completely lacked expression of the CD11a adhesion to calculate the cytotoxic activity:
molecule, but strongly expressed the CD50 adhesion molecule and MHC class I and class II molecules. Most tumor Figure 2 , bold solid line), and of CD54 and CD58 adhesion molecules ( Figure 3 ). The expression of PBMC were isolated from the blood of four newly diagnosed CD50 was only marginally higher, and the expression of B-CLL patients, and cultured overnight in medium or with CD11a remained low. In contrast, B-CLL cells cocultured with CD40L-transfected mouse fibroblasts. Unstimulated B-CLL CD32-transfected 3T6 cells (control stimulators) displayed a cells and CD40-stimulated B-CLL cells were immunomagnetslightly higher expression of CD54 than unstimulated B-CLL ically purified, irradiated (40 Gy) and used as stimulators for cells, while the other adhesion and costimulatory molecules purified CD4
+ , CD8 + , or CD3 + allogeneic T cells from healthy were unchanged ( Figure 3 ). This indicates that CD40L moldonors. As shown in Table 1 , only the CD40-triggered B-CLL ecules were specifically responsible for the strong upregulcells were capable of inducing allogeneic T cell proliferation.
ation of CD54, CD58, CD80 and CD86 and CD40-triggered Interestingly, both purified CD4
+ and (to a lesser extent) CD8 Despite their low proliferation, the upregulation of CD25 and The two signal theory of T cell activation predicts that the HLA-DR expression clearly shows that isolated CD8 + T cells expression of costimulatory molecules limits the generation of were efficiently stimulated by CD40-triggered B-CLL cells.
T cell responses. 28 We therefore studied the role of B7 costimulatory molecules during the induction of demonstrate that B7 costimulatory molecules are also crucial for restimulation of primed B-CLL-reactive T cells, and that We next studied whether CD40-triggered B-CLL cells have the capacity to generate allogeneic T cell cytotoxicity. Isolated cells (99%, 91% and 99% inhibition, respectively, in three experiments performed). Anti-CD80 mAb alone inhibited the CD4 + and CD8 + T cells were cultured with either unstimulated or CD40-triggered B-CLL cells for 5-7 days. Cytotoxic activity proliferative T cell response towards the stimulated tumor cells by 81%, 53% and 98%, respectively. Anti-CD86 mAb of the allogeneic T cells was investigated immediately after culture in two different cytotoxicity assays. LAK-like activity had a variable effect (from 0 to 88%). This variability correlates with the relatively low CD86 expression level (mean of the cytotoxic effector cells was detected by lysis of P815 cells. Resting B-CLL cells were used as a target to measure fluorescence intensity 51) on the CD40-triggered B-CLL cells of patient 3, when compared with the stimulated tumor cells cytotoxic T lymphocyte (CTL) activity generated towards the tumor. As shown in Table 3 , no CTL activity was generated of patients 2 (mean fluorescence intensity 203) and 4 (mean fluorescence intensity 243). The expression levels of CD11a, when T cells were cultured with unstimulated B-CLL stimulator cells. In contrast, when CD40-triggered B-CLL cells were CD50, CD54, CD58, and CD80 molecules on the CD40-triggered tumor cells of the three patients were similar (data not used as stimulators and CD8 + T cells as responders, CTL activity was generated against the unmanipulated tumor cells shown). Two-color FACS analysis of the responding T cells further demonstrated that CTLA4-Ig strongly interfered with of the three patients investigated. On two occasions, CD40-triggered B-CLL cells were used to generate CTL activity in the upregulation of CD25 and HLA-DR activation markers when compared to the conditions with anti-CD80 mAb or both CD4 + and CD8 + allogeneic T cells. As shown in Table 3 , CTL activity was only detected within the CD8 + T cell subset. anti-CD86 mAb alone (Figure 4b) . In a separate experiment, the proliferative response of primed CD3 + T cells during These results show that isolated CD8 + T cells can be triggered to develop CTL activity in the absence of help from CD4 + T restimulation with CD40-triggered B-CLL cells of patient 4 (35587 ± 5530 c.p.m.) was also completely blocked by the cells, and that once activated, these CD8 + CTL can lyse their targets in the absence of B7-CD28 interaction. addition of CTLA4-Ig (357 ± 67 c.p.m.). These observations We demonstrate in this paper that CD40 triggering of B-CLL cells upregulates their expression of adhesion and costimuwere harvested and rested overnight in medium. The T cells were recultured with irradiated stimulator cells for 3-4 days latory molecules, and strongly enhances their capacity to induce allogeneic T cell proliferation and tumor-directed cytoand T cell proliferation (n = 2) and cytotoxicity (n = 1) was determined. Figure 5 shows that primed allogeneic CD8 + T toxicity.
Culture of allogeneic T cells with unstimulated B-CLL cells does not cause unresponsiveness or anergy
577 Table 3 Cytotoxic 
Figure 4
The proliferative response and activation marker expression on allogeneic T cells during culture with CD40-triggered B-CLL cells is reduced by blocking of B7 costimulatory molecules. Inhibition experiments were performed by adding control mAb, anti-CD80 mAb, anti-CD86 mAb, or CTLA4-Ig fusion protein at the beginning of the cultures. Inhibition of allogeneic T cell proliferation (a) and activation marker expression (b) is shown. CD4
+ (experiments 1 Figure 5 Activated CD8 + T cells still require B7-CD28 interaction and 2) and CD3 + T cells (experiment 3) were from normal donors for restimulation. The proliferative response of allogeneic CD8 + T cells and were purified with Dynabeads and Lympho-KWIK-T, respectively.
was measured upon restimulation with either CD40-triggered (CD40-Proliferation was measured as Other investigators also observed that fresh B-CLL cells are unable to stimulate allogeneic T cell proliferation despite clear CD8 + allogeneic T cells. The latter observation confirms and extends the findings of Yellin et al 20 with total CD3 + T cells, expression of MHC class I and class II molecules. 8, 9, 20 Furthermore, resting B cells from healthy donors are equally inefand demonstrates that CD40-triggered B-CLL cells can trigger significant proliferation of CD8 + (allogeneic) T cells in the ficient stimulators for allogeneic T cells. 29 The dim expression of CD54 and CD58 adhesion molecules and of CD80 and absence of CD4 + T cell help. The expression of both CD80 and CD86 costimulatory molecules appeared important for CD86 costimulatory molecules on both normal resting B cells and B-CLL cells is apparently insufficient for efficient T cell allogeneic T cell proliferation, since this was nearly completely inhibited by anti-CD80 and/or anti-CD86 mAb alone activation.
CD40 triggering of B-CLL cells with CD40L-expressing in two of the three experiments, and was completely abrogated by CTLA4-Ig fusion protein, which blocks both CD80 mouse fibroblasts resulted in a rapid upregulation of CD80 and CD86 costimulatory molecules, and strongly enhanced and CD86. These observations suggest that both costimulatory molecules contribute to reach a critical 'costimulatory threshtheir stimulatory capacity towards purified CD4
+ as well as cytotoxic activity in isolated CD4 + and CD8 + allogeneic T cell subsets, tumor-directed cytotoxicity was only induced within the CD8 + T cell subset. This is in agreement with Plumas et al, 33 who recently observed that the CTL activity of allogeneic T cells against malignant B cells from non-Hodgkin's lymphomas was exerted by CD8 + T cells. Moreover, in our in vitro experiments cytotoxicity was induced within purified CD8 + T cells, indicating that cytotoxicity generation by CD40-triggered B-CLL cells may also occur without CD4 + T cell help. Direct costimulation of CD8 + T cells by B7-positive tumor cells has been observed in vivo too. 13 These findings clearly illustrate the importance of B7 expression for the induction of CTL responses.
The secondary response of primed B-CLL-reactive T cells towards CD40-triggered B-CLL cells was nearly completely abolished by CTLA4-Ig, indicating that B7 costimulation is also crucial for restimulation of pre-activated B-CLL-reactive T cells. Furthermore, primed B-CLL-reactive T cells demonstrated a very low secondary proliferative response upon restimulation with resting B-CLL cells, illustrating that the dim expression of CD80 and CD86 costimulatory molecules on resting B-CLL cells is insufficient to stimulate primary as well as secondary T cell proliferative responses. This is in contrast to the B7-independent secondary responses of pre-activated T cells towards recall antigens presented by monocytes, 36 which may relate to presentation of other costimulatory molecules by the monocytes. However, using CD40-triggered follicular lymphoma cells as primary stimulators, Schultze et al 22 also found a decreased dependence on costimulatory molecules to subsequently drive the proliferation of primed allogeneic T cells. On the other hand, we observed that once allogeneic T cell cytotoxicity was generated by the CD40-triggered B-CLL cells, this was maintained or even enhanced after a secondary culture period with unstimulated tumor cells. This confirms the observation that CTL effector function, once activated, is stimulated B-CLL cells resulted from previous in vivo induction of tumor-specific anergy by the massive amount of tumor cells usually present in CLL patients. Although we failed to old' for T cell activation. Furthermore, since the dim expression of CD86 on the stimulated B-CLL cells of patient induce allospecific anergy in allogeneic T cells in vitro by coculture with irradiated unstimulated B-CLL cells at a stimu-3 was still sufficient for allogeneic T cell activation in the presence of anti-CD80 mAb, other adhesion and/or costimulatory lator:responder ratio of 1:4, higher stimulator:responder ratios may be needed to induce anergy. molecules (which are also upregulated by CD40 triggering) presumably reduce the B7 costimulatory threshold. Although Collectively, our findings indicate that B-CLL represents an ideal candidate for further investigation of potential immunothe CD54 and CD58 adhesion molecules may importantly contribute to (antitumor) T cell responses, [30] [31] [32] their strong therapeutic strategies since: (1) large numbers of tumor cells can be easily obtained from small samples of peripheral upregulation on CD40-triggered B-CLL cells was, however, insufficient to stimulate allogeneic T cells in the absence of blood; (2) freshly collected B-CLL cells can be maintained in culture for some weeks; (3) coculture of B-CLL cells with B7 costimulation. In accordance with our findings, allogeneic T cell proliferative responses against malignant B cells from CD40L-expressing cells results in a rapid endogenous upregulation of adhesion and costimulatory molecules; and (4) both non-Hodgkin's lymphomas were also strongly inhibited by blocking CD80 and/or CD86 costimulatory molecules. enhances their immunogenicity towards allogeneic T cells, stimulates further research to determine whether additional toxicity 34 and to lysis by normal or autologous LAK cells, 35 but our data show that they are vulnerable to CTL effector costimulatory factors may break the in vitro unresponsiveness of autologous T cells towards CD40-triggered tumor cells; mechanisms. On two occasions where we tried to generate
